NCT01528111View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Primary Open-angle GlaucomaOcular Hypertension
Interventions
DRUG

LX7101 (0.125%)

Subjects will receive 0.125% LX7101

DRUG

LX7101 (0.25%)

Subjects will receive 0.25% LX7101

DRUG

LX7101 Vehicle

Subjects will receive vehicle

Trial Locations (5)

30260

Lexicon Investigational Site, Morrow

38119

Lexicon Investigational Site, Memphis

77025

Lexicon Investigational Site, Houston

78209

Lexicon Investigational Site, San Antonio

78731

Lexicon Investigational Site, Austin

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY